— First patient treated at Cardiff University, Wales (UK) — Oxford, UK – 10 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical…
Click here to view the prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR…
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading…
Click here to read the full announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR…
— MHRA approval received to enable GMP manufacturing for clinical supply — Oxford, UK – 8 June 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based…
Oxford, UK – 11 May 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the…
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)…
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)…
Click here to download the full 2011 preliminary results statement.Click here to download the 2011 results slide deck.Click here to listen to the audio replay file. Oxford, UK – 6 March 2012: Oxford BioMedica…
—Appointment of new Chief Financial Officer and Company Secretary — Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today…
— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function — Oxford, UK – 15 December 2011: Oxford BioMedica plc (“Oxford BioMedica” or…
Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period…